Navigation Links
Valeant Launches Senior Notes Offering
Date:2/3/2011

MISSISSAUGA, Ontario, Feb. 3, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) (the "Company") announced today that Valeant Pharmaceuticals International ("Valeant"), its wholly owned indirect subsidiary, launched its offer of approximately $650 million aggregate principal amount of senior unsecured notes (the "Notes").

The Notes will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to qualified institutional buyers under Rule 144A of the Securities Act and outside the United States under Regulation S of the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

Valeant intends to use the net proceeds from the offering of the Notes to finance the acquisition of PharmaSwiss S.A., a privately-owned branded generics and over-the-counter (OTC) pharmaceutical company based in Zug, Switzerland and the acquisition of all U.S. and Canadian rights to non-ophthalmic topical formulations of Zovirax® from GlaxoSmithKline and to pay fees and expenses in connection with these acquisitions and for general corporate purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.About ValeantValeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.

Caution Regarding Forward-Looking Information and "Safe Harbor" StatementThis press release may contain forward-looking statements, including, but not limited to, our financing plans. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and risks and uncertainties relating to the proposed merger, as detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.Contact Information:Laurie W. Little949-461-6002laurie.little@valeant.com(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals to Acquire PharmaSwiss S.A.
2. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
3. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
4. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
5. Valeant Announces Pricing of Senior Notes
6. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
7. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
8. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
9. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
10. Valeant and Biovail Announce Results of Special Meetings of Shareholders
11. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 17, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... today announced that it has implemented a ... the Zimmer Biomet management team. Effective January 23, ... the position of President, Americas and join the ... served as Zimmer Biomet,s Vice President of U.S. ...
(Date:1/17/2017)... Research and Markets has announced the addition of the ... ... laparotomy sponges market to grow at a CAGR of 7.94% during ... 2016-2020, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:1/17/2017)... BELLEFONTE, Pa. , Jan. 17, 2017 /PRNewswire/ ... Medical, Inc.(AMI) announces the addition of 6 senior ... of the TubeClear® System.  These sales leaders were ... recently acquired medical device company. Repeatedly recognized for ... of exceeding customer expectations and establishing relationships with ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... 2017 , ... Anesthesia Progress – Everyone wants less pain during ... option for each patient. Dentists have several general anesthesia alternatives and finding the right ... the Tokyo Dental College in Tokyo, Japan wanted to find out which anesthetic was ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Healthful-Flex. , The company, owned and operated by Ed Stroup, was created ... reasonable price with the highest level of customer service. Healthful Balance products can ...
(Date:1/17/2017)... Clemente, CA (PRWEB) , ... January 17, 2017 ... ... Diego County, as well as Palm Desert, is opening a new office in ... Brainsway deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling ...
(Date:1/17/2017)... ... 2017 , ... A prescription medication bottle, pocket knife, luggage and a solar-powered ... Product Design Challenge , the Cradle to Cradle Products Innovation Institute has ... scheduled to run through early 2018. The challenges are presented by the Institute in ...
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... Livionex, ... the results of a double blind clinical study for its dental gel that shows ... leading national brand of toothpaste containing triclosan. The study was conducted at the Beckman ...
Breaking Medicine News(10 mins):